Research into Parkinson's disease has identified alpha synuclein as a key target for potential treatments. Various approaches are being explored, including compounds that target mitochondrial damage and immune proteins, with some showing promise in slowing or stopping the disease's progression. The development of these treatments is ongoing, with some candidates advancing to new phases of clinical testing, while others have been discontinued due to unsuccessful trial results.